Lixisenatide

Overview

Lixisenatide is a 44-amino-acid exendin-4 analog (marketed as Lyxumia/Adlyxin) that activates the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon, and delay gastric emptying. Because it is short-acting relative to weekly agents, its most prominent effect is on postprandial glucose, making it useful in combination with basal insulin (also co-formulated with insulin glargine as iGlarLixi).

The ELIXA trial was the first completed cardiovascular outcomes trial for a GLP-1 receptor agonist. In more than 6,000 patients with type 2 diabetes and a recent acute coronary syndrome, once-daily lixisenatide 20 mcg was non-inferior to placebo for major cardiovascular events and did not increase heart-failure hospitalization, confirming cardiovascular safety without demonstrating superiority.

The most common adverse effects are nausea and vomiting, mitigated by starting at 10 mcg daily for two weeks before escalating to the 20 mcg maintenance dose.

Mechanism of Action

By activating pancreatic beta-cell GLP-1 receptors, lixisenatide augments insulin release only when glucose is elevated, limiting hypoglycemia. Its pronounced effect on gastric emptying is why it lowers post-meal glucose excursions more than fasting glucose, complementing the fasting-glucose control provided by basal insulin. Central GLP-1 signaling contributes modest appetite suppression and weight effect.

Reconstitution Calculator